Evidence map›Paper›PMID 38988566›Full record

ReviewHeliyon2024

Lomitapide repurposing for treatment of malignancies: A promising direction.

Hua-Tao Wu, Bing-Xuan Wu, Ze-Xuan Fang, Zheng Wu, Yan-Yu Hou, Yu Deng, Yu-Kun Cui, Jing Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hua-Tao WuDepartment of General Surgery, the First Affiliated Hospital of Shantou University Medical College, Shantou, 515041, China.
Bing-Xuan WuDepartment of General Surgery, the First Affiliated Hospital of Shantou University Medical College, Shantou, 515041, China.
Ze-Xuan FangThe Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
Zheng WuThe Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
Yan-Yu HouThe Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
Yu DengDepartment of General Surgery, the First Affiliated Hospital of Shantou University Medical College, Shantou, 515041, China.
Yu-Kun CuiThe Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
Jing LiuThe Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of novel drugs from basic science to clinical practice requires several years, much effort, and cost. Drug repurposing can promote the utilization of clinical drugs in cancer therapy. Recent studies have shown the potential effects of lomitapide on treating malignancies, which is currently used for the treatment of familial hypercholesterolemia. We systematically review possible functions and mechanisms of lomitapide as an anti-tumor compound, regarding the aspects of apoptosis, autophagy, and metabolism of tumor cells, to support repurposing lomitapide for the clinical treatment of tumors.

Indexed as

CancerLomitapidemTOR signalingRepurposingTherapy

Identifiers

PMID38988566
PMCPMC11234027

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.